Wall Street Zen Upgrades KORU Medical Systems (NASDAQ:KRMD) to “Strong-Buy”

KORU Medical Systems (NASDAQ:KRMD) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

A number of other brokerages have also recently issued reports on KRMD. Lake Street Capital lifted their target price on KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday. Canaccord Genuity Group upped their target price on KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.88.

KORU Medical Systems Trading Down 3.9%

KORU Medical Systems stock opened at $6.23 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.92 and a current ratio of 2.48. The firm has a market cap of $288.57 million, a price-to-earnings ratio of -77.88 and a beta of 0.58. KORU Medical Systems has a 1 year low of $1.86 and a 1 year high of $6.61. The firm’s 50 day moving average price is $4.97 and its two-hundred day moving average price is $4.19.

Institutional Trading of KORU Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of the business. Acuitas Investments LLC grew its holdings in shares of KORU Medical Systems by 89.6% during the third quarter. Acuitas Investments LLC now owns 763,088 shares of the company’s stock valued at $2,923,000 after buying an additional 360,594 shares in the last quarter. Topline Capital Management LLC boosted its position in KORU Medical Systems by 1.1% during the 3rd quarter. Topline Capital Management LLC now owns 3,648,240 shares of the company’s stock worth $13,973,000 after acquiring an additional 39,893 shares during the period. BNP Paribas Financial Markets grew its stake in KORU Medical Systems by 52.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after acquiring an additional 3,478 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of KORU Medical Systems by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,145,772 shares of the company’s stock valued at $8,218,000 after purchasing an additional 60,109 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in shares of KORU Medical Systems in the 2nd quarter valued at about $59,000. Institutional investors and hedge funds own 58.60% of the company’s stock.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.